RCT Comparing Avatar Intervention to Supportive Intervention to Reduce Cannabis Use in Patients With Psychotic Disorders
Launched by CIUSSS DE L'EST DE L'ÎLE DE MONTRÉAL · Jan 20, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called the Avatar Intervention to see if it can help people with psychotic disorders reduce their cannabis use more effectively than traditional supportive counseling. The trial is open to adults aged 18 and older who have been diagnosed with cannabis use disorder and have conditions like schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic symptoms. Participants will be selected based on specific criteria to ensure they are suitable for the study.
If you or someone you know is eligible and decides to participate, you can expect to receive either the Avatar Intervention or supportive counseling. Throughout the trial, researchers will monitor your progress and help you manage your cannabis use. It's important to note that individuals with other substance use disorders, ongoing treatments for cannabis use, or certain health conditions will not be eligible to join. The trial is currently recruiting participants, and your involvement could contribute to finding better ways to support people with these challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Males or females over 18 years of age who meet the DSM-5 criteria for CUD (≥4 criteria) ;
- • Patients will meet the DSM-5 criteria for schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic symptoms. Diagnoses will be established with the Structured Interview for DSM-5 (SCID-5).
- Exclusion Criteria:
- • Current SUD for a substance other than cannabis ;
- • Ongoing pharmacological or psychological treatment for CUD ;
- • Ongoing detoxification for cannabis withdrawal ;
- • Presence of neurological disorders ;
- • Presence of a severe and unstable physical illness ;
- • Inability to provide consent.
About Ciusss De L'est De L'île De Montréal
Ciusss de l'Est de l'Île de Montréal is a leading healthcare organization dedicated to enhancing the health and well-being of the communities it serves. As a prominent clinical trial sponsor, Ciusss de l'Est conducts innovative research aimed at advancing medical knowledge and improving patient outcomes. With a focus on collaboration and ethical standards, the organization fosters a multidisciplinary approach to clinical research, ensuring rigorous methodologies and comprehensive patient care. Through its commitment to scientific excellence and community health, Ciusss de l'Est plays a vital role in shaping the future of healthcare in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Trial Officials
Alexandre Dumais, MD, PhD
Principal Investigator
University of Montreal, Institut universitaire en santé mentale de Montréal
Stephane Potvin, PhD
Principal Investigator
University of Montreal, Institut universitaire en santé mentale de Montréal
Emmanuel Stip, MD, MSc
Study Chair
United Arab Emirates University
Amal Abdel Baki, MD, MSc
Study Chair
University of Montreal, Centre hospitalier de l'Université de Montréal
Robert-Paul Juster, PhD
Study Chair
University of Montreal, Institut universitaire en santé mentale de Montréal
Marie-Hélène Goulet, PhD
Study Chair
University of Montreal, Institut universitaire en santé mentale de Montréal
Luigi De Benedictis, MD
Study Chair
Institut universitaire en santé mentale de Montréal
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials